Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Land & Improvements (2021 - 2025)

Historic Land & Improvements for Abvc Biopharma (ABVC) over the last 4 years, with Q3 2025 value amounting to $4.2 million.

  • Abvc Biopharma's Land & Improvements changed N/A to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year change of. This contributed to the annual value of $338966.0 for FY2024, which is N/A changed from last year.
  • Per Abvc Biopharma's latest filing, its Land & Improvements stood at $4.2 million for Q3 2025.
  • Over the past 5 years, Abvc Biopharma's Land & Improvements peaked at $4.2 million during Q3 2025, and registered a low of $334520.0 during Q1 2025.
  • For the 4-year period, Abvc Biopharma's Land & Improvements averaged around $1.0 million, with its median value being $370084.0 (2022).
  • Over the last 5 years, Abvc Biopharma's Land & Improvements had its largest YoY gain of 972.23% in 2022, and its largest YoY loss of 972.23% in 2022.
  • Over the past 4 years, Abvc Biopharma's Land & Improvements (Quarter) stood at $400091.0 in 2021, then dropped by 9.72% to $361193.0 in 2022, then dropped by 6.15% to $338966.0 in 2024, then soared by 1145.7% to $4.2 million in 2025.
  • Its Land & Improvements was $4.2 million in Q3 2025, compared to $378975.0 in Q2 2025 and $334520.0 in Q1 2025.